87120-73-8

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
TERT-BUTYL 4-(2-NITROPHENYLAMINO)PIPERIDINE-1-CARBOXYLATE is used as a chemical intermediate for the synthesis of pharmaceutical compounds. Its unique structure, including the nitrophenylamino group, may contribute to the development of new drugs with specific therapeutic properties.
Used in Organic Synthesis:
In the field of organic synthesis, TERT-BUTYL 4-(2-NITROPHENYLAMINO)PIPERIDINE-1-CARBOXYLATE serves as a building block for the preparation of various piperidine derivatives. These derivatives can be further utilized in the creation of complex organic molecules with potential applications in different industries.
Used in Chemical Research:
TERT-BUTYL 4-(2-NITROPHENYLAMINO)PIPERIDINE-1-CARBOXYLATE is used as a research tool in chemical laboratories to study the properties and reactions of ester derivatives and piperidine carboxylates. Its reactivity and functional groups can provide insights into the development of new synthetic methods and applications.
Used in Controlled Laboratory Settings:
Due to its potential cytotoxicity and other hazards, TERT-BUTYL 4-(2-NITROPHENYLAMINO)PIPERIDINE-1-CARBOXYLATE is used with caution in controlled laboratory settings. Proper handling and safety measures are essential to minimize risks and ensure the safe use of TERT-BUTYL 4-(2-NITROPHENYLAMINO)PIPERIDINE-1-CARBOXYLATE in research and development processes.

InChI:InChI=1/C16H23N3O4/c1-16(2,3)23-15(20)18-10-8-12(9-11-18)17-13-6-4-5-7-14(13)19(21)22/h4-7,12,17H,8-11H2,1-3H3

Upstream product

• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 88-73-3 2-Chloronitrobenzene 
• 1493-27-2 ortho-nitrofluorobenzene 

Downstream Products

• 1352721-62-0 4-{2-tert-butoxycarbonylimino-3-[1-(5-chloro-2-nitro-phenyl)-piperidin-4-yl]-2,3-dihydro-benzoimidazol-1-ylmethyl}-benzotriazole-1-carboxylic acid tert-butyl ester 
• 1352721-63-1 1-(1H-benzotriazol-4-ylmethyl)-3-[1-(5-chloro-2-nitro-phenyl)-piperidin-4-yl]-1,3-dihydro-benzoimidazol-2-ylideneamine 
• 1352721-64-2 1-[1-(5-chloro-2-nitro-phenyl)-piperidin-4-yl]-1H-benzoimidazol-2-ylamine 
• 1352721-16-4 N-(4-chloro-2-{4-[2-imino-3-(1H-indol-4-ylmethyl)-2,3-dihydro-benzoimidazol-1-yl]-piperidin-1-yl}-phenyl)-acetamide 
• 1352721-51-7 4-{3-[1-(2-amino-5-chloro-phenyl)-piperidin-4-yl]-2-[tert-butoxycarbonylimino]-2,3-dihydro-benzoimidazol-1-ylmethyl}-indole-1-carboxylic acid tert-butyl ester 
• 53786-10-0 1,3-dihydro-1-methyl-3-(4-piperidinyl)-2H-benzimidazol-2-one 
• 20662-53-7 4-(2-keto-1-benzimidazolinyl)piperidine 
• 1575817-32-1 N-(1-(1-acryloylpiperidin-4-yl)-1H-benzo[d]imidazol-2-yl)-4-chlorobenzamide 
• 1575817-31-0 4-chloro-N-(1-(1-(2-cyano-4-methylpent-2-enoyl)piperidin-4-yl)-1H-benzo[d]imidazol-2-yl)benzamide 
• 1575819-11-2 4-chloro-N-(1-(1-(2-cyanoacetyl)piperidin-4-yl)-1H-benzo[d]imidazol-2-yl)benzamide 
• 1575819-10-1 4-chloro-N-(1-(piperidin-4-yl)-1H-benzo[d]imidazol-2-yl)benzamide hydrochloride 
• 1575819-09-8 tert-butyl 4-(2-(4-chlorobenzamido)-1H-benzo[d]imidazol-1-yl)piperidine-1-carboxylate 
• 87120-81-8 1,3-dihydro-1-(1-tert-butyloxycarbonylpiperidin-4-yl)-2H-benzimidazol-2-one 
• 1352721-53-9 1-[1-(5-chloro-2-nitro-phenyl)-piperidin-4-yl]-3-(1H-indol-4-ylmethyl)-1,3-dihydro-benzoimidazol-2-ylideneamine 

Relevant academic research and scientific papers

Synthesis and antimicrobial activity of some new of 2-(furan-2-yl)-1-(piperidin-4-yl)-1H-benzo[d]imidazole derivatives

We report a series of new heterocyclic compounds containing the imidazole scaffold were synthesized such as 2-(furan-2-yl)-1-(piperidine-4-yl)-1H-benzo[d]imidazole derivative. Due to the biological activities of imidazole as antimicrobial agents, in the p

Chemical modulation of the 1-(Piperidin-4-yl)-1,3-dihydro-2h-benzo[d]imidazole-2-one scaffold as a novel NLRP3 inhibitor

In the search for new chemical scaffolds able to afford NLRP3 inflammasome inhibitors, we used a pharmacophore-hybridization strategy by combining the structure of the acrylic acid derivative INF39 with the 1-(piperidin-4-yl)1,3-dihydro-2H-benzo[d]imidazole-2-one substructure present in HS203873, a recently identified NLRP3 binder. A series of differently modulated benzo[d]imidazole-2-one derivatives were designed and synthesised. The obtained compounds were screened in vitro to test their ability to inhibit NLRP3-dependent pyroptosis and IL-1β release in PMA-differentiated THP-1 cells stimulated with LPS/ATP. The selected compounds were evaluated for their ability to reduce the ATPase activity of human recombinant NLRP3 using a newly developed assay. From this screening, compounds 9, 13 and 18, able to concentration-dependently inhibit IL-1β release in LPS/ATP-stimulated human macrophages, emerged as the most promising NLRP3 inhibitors of the series. Computational simulations were applied for building the first complete model of the NLRP3 inactive state and for identifying possible binding sites available to the tested compounds. The analyses led us to suggest a mechanism of protein– ligand binding that might explain the activity of the compounds.

Discovery of a Bromodomain and Extraterminal Inhibitor with a Low Predicted Human Dose through Synergistic Use of Encoded Library Technology and Fragment Screening

The bromodomain and extraterminal (BET) family of bromodomain-containing proteins are important regulators of the epigenome through their ability to recognize N-acetyl lysine (KAc) post-translational modifications on histone tails. These interactions have been implicated in various disease states and, consequently, disruption of BET-KAc binding has emerged as an attractive therapeutic strategy with a number of small molecule inhibitors now under investigation in the clinic. However, until the utility of these advanced candidates is fully assessed by these trials, there remains scope for the discovery of inhibitors from new chemotypes with alternative physicochemical, pharmacokinetic, and pharmacodynamic profiles. Herein, we describe the discovery of a candidate-quality dimethylpyridone benzimidazole compound which originated from the hybridization of a dimethylphenol benzimidazole series, identified using encoded library technology, with an N-methyl pyridone series identified through fragment screening. Optimization via structure- and property-based design led to I-BET469, which possesses favorable oral pharmacokinetic properties, displays activity in vivo, and is projected to have a low human efficacious dose.

Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias

While mu opioid receptor (MOR) agonists are especially effective as broad-spectrum pain relievers, it has been exceptionally difficult to achieve a clear separation of analgesia from many problematic side effects. Recently, many groups have sought MOR agonists that induce minimal βarrestin-mediated signaling because MOR agonist-treated βarrestin2 knockout mice were found to display enhanced antinociceptive effects with significantly less respiratory depression and tachyphylaxis. Substantial data now exists to support the premise that G protein signaling biased MOR agonists can be effective analgesic agents. We recently showed that, within a chemical series, the degree of bias correlates linearly with the magnitude of the respiratory safety index. Herein we describe the synthesis and optimization of piperidine benzimidazolone MOR agonists that together display a wide range of bias (G/βarr2). We identify structural features affecting potency and maximizing bias and show that many compounds have desirable properties, such as long half-lives and high brain penetration.

The preparation method of the deuterium generation of Mauzy is special

The invention discloses a preparation method of deuterated pimozide. The pimozide-d4 is synthesized from 4-bromopentafluorobenzene-d4 through eight steps. The provided preparation method has the advantages of reasonable technological design, simple operation, easy product separation and purification, easily-available raw materials, high yield, and high purity. The isotope abundance of the obtained target product is high. The prepared stable isotope-labeled pimozide-d4 can be well applied to clinical pharmacokinetics researches, so people can acknowledge the metabolism process and action mechanism of pimozide in human body more precisely and conveniently, and thus the deuterated pimozide has an important application value.

BENZIMIDAZOLE DERIVATIVES AS RLK and ITK INHIBITORS

The present disclosure is directed to certain inhibitors of RLK and ITK of formula (I), pharmaceutical compositions comprising such compounds, and method of treating diseases mediated by inhibition of RLK and ITK.

BENZIMIDAZOLE DERIVATIVES AS ITK INHIBITORS

The present disclosure is directed to certain inhibitors of kinases such as ITK, BLK, BMX, BTK, JAK3, TEC, TXK, HER2 (ERBB2), or HER4 (ERBB4), in particular ITK, pharmaceutical compositions comprising such compounds, and method of treating diseases mediated by such kinases.

Non-benzimidazole containing inhibitors of respiratory syncytial virus

Several non-benzimidazole containing inhibitors of respiratory syncytial virus are described. Core template modification, analysis of antiviral activity, physicochemistry and optimisation of properties led to the thiazole-imidazole 13, that showed a good potency and pharmacokinetic profile in the rat.

Novel N-substituted benzimidazole CXCR4 antagonists as potential anti-HIV agents

The lead optimization of a series of N-substituted benzimidazole CXCR4 antagonists is described. Side chain modifications and stereochemical optimization led to substantial improvements in potency and protein shift to afford compounds with low nanomolar a

CHEMICAL COMPOUNDS

The present invention provides novel compounds that demonstrate protective effects on target cells from HIV infection in a manner as to bind specifically to the chemokine receptor, and which affect the binding of the natural ligand or chemokine to a receptor such as CXCR4 and/or CCR5 of a target cell.